Roivant Sciences Ltd. 8-K

What Happened
Roivant Sciences Ltd. (ROIV) filed an 8-K on April 2, 2026 announcing preliminary, unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026. The company reported that for the three months ended March 31, 2026 it repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 million (excluding fees and commission). The filing also attached a press release (Exhibit 99.1) dated April 2, 2026 announcing a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris and reporting topline results from Immunovant’s two Phase 3 studies of batoclimab for adults with active, moderate‑to‑severe thyroid eye disease.

Key Details

• Preliminary cash, cash equivalents and marketable securities: ~ $4.3 billion (as of March 31, 2026).
• Share repurchases (Q1 2026): 3,956,362 common shares repurchased for ~ $109.7 million (ex‑fees).
• Clinical program update: Priovant launching a Phase 2b/3 program for brepocitinib in lichen planopilaris (press release dated April 2, 2026).
• Immunovant update: Press release includes topline results from two Phase 3 batoclimab trials in thyroid eye disease (details included in Exhibit 99.1).

Why It Matters
The reported ~$4.3B liquidity position provides a snapshot of Roivant’s cash resources as of March 31, 2026, which is a key input for assessing funding for ongoing programs and operations. The company’s repurchase of nearly 4.0 million shares for about $110 million reduces outstanding share count and reflects capital allocation activity. The Priovant brepocitinib Phase 2b/3 program and Immunovant topline Phase 3 results are material pipeline developments; investors should review the attached April 2, 2026 press release (Exhibit 99.1) for full trial details and outcomes.